The NCI Board of Scientific Advisors has approved nine new and reissue concepts—Request for Applications, Cooperative Agreement, Request for Proposals, and Program Announcements with special receipt, referral and review.
Any way you look at it, Northwell Health, New York’s largest health system, took a massive hit from COVID-19.
Keytruda was approved by FDA for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
Selinexor (Xpovio) was granted accelerated approval from FDA for adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
Myovant Sciences' New Drug Application for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer has been accepted for Priority Review by FDA.
Keytruda was approved by the National Medical Products Administration in China as monotherapy for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) as determined by a fully validated test, following failure of one prior line of systemic therapy.
FDA has launched Project Patient Voice, an initiative of the FDA's Oncology Center of Excellence that aims to communicate patient-reported outcomes from cancer clinical trials, making them more accessible to the public.
Black patients are better represented in taxpayer-funded clinical trials testing new cancer treatments compared to trials run by pharmaceutical companies, according to a study conducted by SWOG Cancer Research Network, a member of NCI's National Clinical Trials Network.
A computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology, the current standard for follow-up of women who test positive with primary human papillomavirus screening.
The phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, and whose tumors had PTEN loss.
